Merck's earnings call displays a generally positive outlook for the short term, focusing on strong operational performance and strategic initiatives. With a 10% increase in non-GAAP EPS in 2011 and continued investment in their pipeline, the company seems to be mitigating headwinds like the SINGULAIR patent expiration. The successful launches and growth in emerging markets, as well as strong cash returns to shareholders, signal confidence in near-term stability. However, challenges in the EU and the looming patent expiry might weigh on performance, though immediate impact appears controlled.
[1]